BRIEF—Therillia acquires Tavec Pharma

Therillia Development Co, a Montreal-based subsidiary of Sanderling Ventures Canada investor in early-stage biotech companies, has acquired Tavec Pharmaceuticals, the leading therapeutic exosome company and is moving its head office from New York to Montreal.

Financial terms of the transaction were not disclosed.

Tavec is an early stage therapeutics company focused on developing the next generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes, packets of pinched off membrane which penetrate solid tumors, in particular liver cancers.

Created in New York in 2015, Tavec received seed funding and has successfully completed pre-clinical studies.

It is currently working on developing its filings in Quebec to initiate clinical trials in liver cancers and chronic liver diseases.

"We are very excited to be moving this unique technology into the clinic in the near future in Quebec," indicated Dr. Fred Hochberg, one of the founders of Tavec.